This approach is justified since post-menopausal breast cancer accounts for two-thirds of breast cancer cases amongst high risk women (with a 16-40% lifetime risk), 40% of cases amongst BRCA1 carriers and 50% of cases amongst BRCA2 carriers [33]. The gene discussed is BRCA1; the disease is breast carcinoma.